{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Longeveron",
            "NStudiesAvail": 430108,
            "NStudiesFound": 8,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 8,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change from baseline in 6MWT compared to placebo at 180 days post-infusion"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change from baseline in 6 Minute Walk Test (6MWT) compared to placebo"
                        ],
                        "NCTId": [
                              "NCT03169231"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Is life-threatening (e.g., stroke or non-fatal pulmonary embolism).\nRequires inpatient hospitalization or prolongation of existing hospitalization.\nResults in persistent or significant disability/incapacity.\nResults in death\nResults in other clinically significant untoward laboratory test result(s) or medical condition(s), determined per Investigator's judgment.",
                              "Measurements of validated hemagglutination inhibition (HAI) assays at follow up visits."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences within 30 days after infusion as assessed by the following:",
                              "The ability of Lomecel-B (LMSC) treatment to improve inactivation of influenza virus as assessed by validated hemagglutination inhibition (HAI) assays."
                        ],
                        "NCTId": [
                              "NCT02982915"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of any treatment-emergent serious adverse event (TE-SAE), defined as one or more of the following untoward medical occurrences happening within the first 30 days after infusion.\n\nLife-threatening event (e.g., stroke or non-fatal pulmonary embolism).\nRequires inpatient hospitalization or prolongation of existing hospitalization.\nResults in persistent or significant disability/incapacity.\nResults in death.\nLeads to other clinically significant untoward laboratory test result(s) or medical condition(s), determined per Investigator's judgement (e.g., new clinically asymptomatic brain microhemorrhages)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "To demonstrate the safety of LMSCs administered to subjects with Alzheimer's disease."
                        ],
                        "NCTId": [
                              "NCT02600130"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The incidence of Treatment-Emergent Serious Adverse Events will be evaluated, including: sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support; aggravation of heart failure; myocardial infarction; unplanned cardiovascular operation for cardiac tamponade; infection during the first month post-treatment; and death."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Safety: To evaluate the safety and feasibility of intramyocardial injection of LMSCs during the Stage II (BDCPA) operation for HLHS via incidence of Treatment-Emergent Serious Adverse Events."
                        ],
                        "NCTId": [
                              "NCT03525418"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [
                              "Anthony Oliva, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Flow-mediated vasodilation (FMD). Endothelial progenitor cell (EPC) function."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Endothelial function: Changes in endothelial function as assessed by the following:"
                        ],
                        "NCTId": [
                              "NCT02587572"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Anthony Oliva, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Terminated"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Monitoring of events includes death, sustained/symptomatic ventricular tachycardia requiring intervention with inotropic support, aggravation of heart failure, new myocardial infarction, unplanned cardiovascular operation for cardiac tamponade and infection in the first month after injection, and serially afterwards."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Monitor major adverse cardiac events"
                        ],
                        "NCTId": [
                              "NCT02398604"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of treatment-emergent serious adverse events (TE-SAEs) within 4 weeks after treatment, defined as one or more of the following untoward medical occurrences happening within the first 4 weeks after treatment.\n\ni. Life-threatening event (e.g., stroke or non-fatal pulmonary embolism). ii. Event requiring inpatient hospitalization or prolongation of existing hospitalization (e.g., for worsening dyspnea).\n\niii. Event resulting in persistent or significant disability/incapacity. iv. Event resulting in death. v. Event leading to other clinically significant untoward laboratory test result(s) or medical condition(s), as determined by the Investigator.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months.",
                              "Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 months, this change in overall assessment will be the outcome in numbers of particants with a change.",
                              "Number of Participants with changes to Overall Assessment Normal vs Abnormal will be collected at Baseline and 6 Months",
                              "Time to recovery of Sp02 to 90% or higher on room air (or the oxygen concentration the patient had before acute illness) after 10 minutes of spontaneous breathing.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in Blood Chemistry testing will be assessed at Baseline and 6 Months.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation testing will be assessed at Baseline and 6 Months.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Hematology testing will be assessed at Baseline and 6 Months."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent Serious Adverse Events",
                              "Number of Participants with Abnormal Clinical Significant Laboratory Values in Hematology.",
                              "Number of Participants with Changes in Echocardiography Overall Assessment",
                              "Number of Participants with Changes to overall assessment of Electrocardiogram",
                              "Time to recovery of Sp02",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Blood Chemistry testing.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Coagulation.",
                              "Number of Participants with Abnormal Clinical Significant Lab Values in the Urinalysis"
                        ],
                        "NCTId": [
                              "NCT04629105"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Joshua M Hare, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [
                              "JHare@med.miami.edu"
                        ],
                        "PointOfContactOrganization": [
                              "University of Miami, Miller School of Medicine - Interdisciplinary Stem Cell Institute (ISCI)"
                        ],
                        "PointOfContactPhone": [
                              "305-243-5579"
                        ],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [
                              "Joshua M Hare, MD"
                        ],
                        "PrimaryCompletionDate": [
                              "October 2, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Incidence of any treatment-emergent serious adverse events (SAE), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.\n\nSerum chemistry: chloride, bicarbonate, blood urea nitrogen (BUN), creatinine, glucose, calcium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (fractionate if total >1.5 times normal), alkaline phosphatase, albumin,\nHematology (Complete blood count): hemoglobin, hematocrit, platelets, white blood cells (WBC), WBC differential"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs)"
                        ],
                        "NCTId": [
                              "NCT02065245"
                        ]
                  }
            ]
      }
}